Business Wire

ExaGrid Announces New Software Version 6.0

Share

ExaGrid®, the industry’s only Tiered Backup Storage solution, today announced the release of software Version 6.0, which begins shipping on September 18, 2020.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200915005278/en/

Key features include:

New Retention Time-Lock for Ransomware Recovery

Retention Time-Lock is a revolutionary approach to protecting backup retention data to enable fast and easy recovery from ransomware.

  • ExaGrid’s two-tier architecture includes a network-facing tier and a non-network-facing tier. ExaGrid alone controls the non-network-facing tier, creating a tiered air gap.
  • Backups are written to the network-facing-tier for fast backup performance. The most recent backups are kept in their full undeduplicated form for fast restores.
  • Data is adaptively deduplicated (for storage cost efficiency) into the non-network-facing tier for long-term retention data. Organizations can have as many days, weeks, months, or years of retention as they require. There is no limit to the number of version retention copies that can be saved.
  • In addition to the long-term retention, ExaGrid offers a policy-driven approach allowing for any delete requests issued to the network-facing tier to be delayed in the non-network-facing tier for a specified number of days, so that backup data will not be deleted when a hacker takes control of the backup application or backup storage.
  • If encrypted data is sent to the network-facing tier, or if any of its data is encrypted, ExaGrid’s repository is protected as all the deduplication objects are immutable because they are never modified.

ExaGrid assumes the hackers will take control of the backup application or the backup storage and will issue delete commands for all backups. ExaGrid has the only non-network-facing tiered backup storage solution (a tiered air gap) with delayed deletes and immutable deduplication objects. This unique approach ensures when a ransomware attack occurs, data can be easily recovered or VMs booted from the ExaGrid Tiered Backup Storage system. Not only can the primary storage be restored, but all retained backups remain intact.

“ExaGrid’s Version 6.0 provides our customers with a new strategy for ransomware recovery: ExaGrid’s Retention Time-Lock, which prevents hackers from deleting data stored in our system’s repository tier as all deletes are delayed by a policy setting. This unique approach allows customers to recover data in the event that the primary storage has become compromised by ransomware or malware,” said Bill Andrews, ExaGrid’s President and CEO. “Unlike other approaches, which require the purchase of an additional storage unit, our approach only requires that customers allocate 2% to 10% of additional repository storage in their existing system with an adjustable delay period, which is in line with our goal of offering the most cost-effective solutions to our customers.”

Security Enhancements (in addition to Ransomware Recovery), New UI Platform, and Other Highlights of Version 6.0

Version 6.0 includes the following security enhancements:

  • New security officer role governs any changes to the Retention Time-Lock policy
  • Optional Two-Factor authentication in web-based user interface using any OAUTH-TOTP app
  • Additional control over SSH access
  • Utilize Active Directory credentials from trusted domains to control share and user interface access
  • New operator role for day to day operations reduces the need for administrator access.
  • Security checklist for quick and easy implementation of best practices
  • Automatic user interface logout after a period of inactivity

Version 6.0 includes the following additional features:

  • User interface improvements provide intuitive details about how the ExaGrid system’s storage capacity is being utilized
  • Streamlined navigation experience
  • Deduplication and replication performance improvements across multiple backup applications

ExaGrid’s Unique Approach: Tiered Backup Storage

Disk-cache Landing Zone (Performance Tier)

  • ExaGrid writes directly to disk for the fastest backup performance
  • ExaGrid restores directly from disk for the fastest restores and VM boots

Long-term Retention Repository (Retention Tier)

  • ExaGrid tiers long-term retention to a deduplicated data repository to reduce storage and resulting storage costs

Backing up to low-cost disk is fast for backups and restores, however, with longer-term retention, the amount of disk required becomes extremely expensive.

To reduce the amount of disk for long-term retention, deduplication appliances reduce the amount of storage and cost, however the deduplication is performed inline on the way to the disk which slows down backups to about one-third the performance of disk. Also, the data is only stored in deduplicated format resulting in extremely slow restores and VM boots as the data has to be reassembled, or rehydrated, for each request. In addition, deduplication appliances are scale-up storage which only adds storage capacity as data grows, resulting in backup windows that continue to grow as data grows, expensive forklift upgrades, and forced product obsolescence.

ExaGrid Tiered Backup Storage writes directly to disk for the fastest backups, and restores directly from disk for the fastest restores and VM boots. ExaGrid then tiers the long-term retention data to a deduplicated data repository to reduce the amount of retention storage and resulting cost. In addition, ExaGrid provides a scale-out architecture where appliances are simply added as data grows. Each appliance includes processor, memory, and network ports, so as data grows, all resources required are available to maintain a fixed-length backup window. This scale-out storage approach eliminates expensive forklift upgrades, and allows for mixing appliances of different sizes and models in the same scale-out system which eliminates product obsolescence while protecting IT investments up front and over time.

ExaGrid offers the best of both worlds by offering low-cost disk for the fastest backup and restore performance tiered to a deduplicated data repository for the lowest cost retention storage. The scale-out storage architecture provides a fixed-length backup window and is low cost up front and over time.

About ExaGrid

ExaGrid provides Tiered Backup Storage with a unique disk-cache Landing Zone, long-term retention repository, and scale-out architecture. ExaGrid’s Landing Zone provides for the fastest backups, restores, and instant VM recoveries. The retention repository offers the lowest cost for long-term retention. ExaGrid’s scale-out architecture includes full appliances and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades and product obsolescence. Visit us at exagrid.com or connect with us on LinkedIn. See what our customers have to say about their own ExaGrid experiences and why they now spend significantly less time on backup in our success stories.

ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.

Contact information

Media:
Kristina O’Connell
ExaGrid
koconnell@exagrid.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial19.9.2020 19:30:00 EESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in combination with Bristol Myers Squibb’s Opdivo® (nivolumab) demonstrated significant improvements across all efficacy endpoints, including overall survival (OS), in previously untreated advanced renal cell carcinoma (RCC).1 Cabometyx® in combination with Opdivo® reduced the risk of death by 40% versus sunitinib (HR: 0.60 [98.89% Confidence Interval [CI]: 0.40–0.89]; p= 0.0010; median OS not reached in either arm). In patients receiving Cabometyx® in combination with Opdivo®, median progression-free survival (PFS), the trial’s primary endpoint, was doubled compared to those receiving sunitinib alone: 16.6 months versus 8.3 months respectively (Hazard Ratio [HR]: 0.51 [95% CI 0.41–0.64], p < 0.0001). In addition, Cabometyx® in combination with Opdivo® demonstrated a superior objective response rate, wit

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EESTPress release

Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95

Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EESTPress release

Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu

Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price

ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom